Share This Page
Suppliers and packagers for PROAIR HFA
✉ Email this page to a colleague
PROAIR HFA
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Teva Branded Pharm | PROAIR HFA | albuterol sulfate | AEROSOL, METERED;INHALATION | 021457 | NDA AUTHORIZED GENERIC | Teva Pharmaceuticals USA, Inc. | 0093-3174-31 | 1 INHALER in 1 CARTON (0093-3174-31) / 200 AEROSOL, METERED in 1 INHALER | 2019-01-16 |
| Teva Branded Pharm | PROAIR HFA | albuterol sulfate | AEROSOL, METERED;INHALATION | 021457 | NDA | NuCare Pharmaceuticals,Inc. | 68071-4940-2 | 200 AEROSOL, METERED in 1 BOX (68071-4940-2) | 2019-01-16 |
| Teva Branded Pharm | PROAIR HFA | albuterol sulfate | AEROSOL, METERED;INHALATION | 021457 | NDA | Proficient Rx LP | 71205-211-85 | 1 INHALER in 1 CARTON (71205-211-85) / 200 AEROSOL, METERED in 1 INHALER | 2019-01-16 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
ppliers for the Pharmaceutical Drug: ProAir HFA
Introduction
ProAir HFA (hydrofluoroalkane inhaler) is a widely prescribed bronchodilator used primarily for the treatment of asthma and COPD. Its active ingredient, albuterol sulfate, provides rapid relief from bronchospasms and improves airflow. As a leading inhaler product, ProAir HFA’s manufacturing and distribution involve a complex network of suppliers across the pharmaceutical supply chain. This analysis explores the key suppliers facilitating the production of ProAir HFA, focusing on active pharmaceutical ingredient (API) providers, device manufacturers, excipient suppliers, and packaging service providers, alongside recent market developments.
Active Pharmaceutical Ingredient (API) Suppliers
1. Teva Pharmaceutical Industries Ltd.
Teva supplies albuterol sulfate API to various inhaler manufacturers, including those producing ProAir HFA. Known for its extensive generic portfolio, Teva’s manufacturing facilities in Israel and India are critical in ensuring consistent, high-quality API supply. Their focus on cost efficiency and strict adherence to GMP (Good Manufacturing Practices) makes them a primary API source for inhaled bronchodilators.
2. Hikma Pharmaceuticals
Hikma, a prominent supplier of albuterol sulfate API, operates manufacturing facilities in Jordan and Europe, ensuring a steady supply for inhaler products globally. Their API quality standards meet regulatory requirements from agencies such as the FDA and EMA. Hikma's role as an API supplier supports multiple inhalation products, including competing formulations of albuterol.
3. Synthesis of API from Contract Manufacturers
Certain API components for ProAir HFA are sourced from third-party contract manufacturing organizations (CMOs) specializing in cyanide chemistry and chlorination processes necessary for albuterol synthesis. Companies such as Jiangsu Hengrui Medicine Co., Ltd. in China have expanded their API production capabilities to meet global demand.
Device and Aerosol Can Suppliers
4. AstraZeneca’s Inhaler Device Manufacturing
ProAir HFA’s inhaler device, though marketed as a product of Teva or other generic producers, relies on high-precision metered-dose inhaler (MDI) technology. AstraZeneca, originally owning patents for inhaler design, played a pivotal role in device development. Contemporary suppliers for inhaler components include AstraZeneca’s partnership manufacturers, which produce valve assemblies, actuator components, and canisters.
5. Recipharm and other Contract Device Manufacturers
Manufacturers like Recipharm (Sweden) and Vectura (UK) have historically been involved in device assembly and finishing processes. These firms specialize in high-quality metal and plastic-based canisters, valves, and actuator components tailored for inhaled medicines.
6. Canister and Valve Suppliers
Key suppliers such as AptarGroup and Ball-PSTON manufacture aerosol valves and canisters that meet pharmaceutical-grade standards. These components are critical to ensuring dose accuracy, product stability, and regulatory compliance.
Excipients and Inactive Ingredient Suppliers
7. Dow Chemical and DuPont
Major chemical companies supply excipients used in aerosol formulations, including propellants, stabilizers, and surfactants. Although the propellant in ProAir HFA is hydrofluoroalkane (HFA), manufacturers source additional excipients for formulation stabilization from these suppliers.
8. Propellant Suppliers
The HFA propellant, primarily HFA-134a (1,1,1,2-tetrafluoroethane), is produced by companies like Chemours (a spin-off from DuPont) and LyondellBasell. These companies supply the refrigerant-grade HFA to inhaler manufacturers, with strict specifications to ensure safety and efficacy.
Packaging and Labeling Service Providers
9. Packaging Material Suppliers
Pharmaceutical-grade plastics, including high-density polyethylene (HDPE) for canister components and printed labels, are sourced from suppliers such as Berry Global and Sealed Air. These firms focus on contamination-free, compliance-certified packaging products, critical for inhaler's sterile environment.
10. Serialization and Labelling Solutions
Advanced serialization providers like Xsess and Amcor handle barcode printing and tamper-evident labeling, ensuring product traceability and regulatory compliance across markets.
Market Dynamics and Recent Developments
Global Manufacturing Footprint
ProAir HFA, as an asthma treatment primarily marketed in the US and Europe, relies on a geographically diverse supply base to mitigate risks related to geopolitical tensions, natural disasters, and regulatory changes. Teva, for instance, has multiple manufacturing facilities across Israel, the US, and India, supporting supply continuity.
Shift Towards Biosimilars and Generics
The expiration of patents for certain inhaler devices and APIs has led to increased involvement from generic manufacturers like Mylan and Sun Pharma, which source from the above-mentioned API and device suppliers to develop competing products. The market landscape is evolving with more entrants and a focus on cost efficiencies.
Supply Chain Challenges
Ongoing global supply chain disruptions, notably in API production and aerosol component manufacturing, have affected lead times and inventory levels. Suppliers have responded with increased inventory holdings and diversification of sourcing strategies.
Regulatory Oversight
Suppliers must navigate rigorous regulatory standards from agencies like the FDA, EMA, and Health Canada. Ensuring compliance in GMP, serialization, and quality management remains central to the supply chain's integrity.
Key Takeaways
- The fundamental inputs for ProAir HFA’s production are primarily supplied by a well-established network of API manufacturers, with Teva and Hikma representing leading suppliers.
- Device components, including valves and canisters, are produced by specialized pharmaceutical equipment manufacturers such as AstraZeneca’s partners and Recipharm.
- Propellants and excipients supplied by companies like Chemours and Dow underpin the formulation's efficacy and safety.
- The global supply chain is increasingly diversified with geographical and strategic considerations, but remains vulnerable to disruptions.
- Ongoing innovation, regulatory adherence, and supply chain resilience are critical to maintaining the product’s market position and meeting global demand.
FAQs
1. Who are the primary API suppliers for ProAir HFA?
Teva and Hikma are the leading API suppliers, providing high-quality albuterol sulfate essential for inhaler formulations.
2. How are inhaler devices for ProAir HFA manufactured?
Device components are manufactured by specialized firms such as Recipharm and through partnerships involving AstraZeneca’s device technology expertise, ensuring precise dosing and regulatory compliance.
3. What role do propellant suppliers play in ProAir HFA’s supply chain?
Chemours and LyondellBasell produce the HFA-134a propellant, critical for aerosol delivery, and their supply continuity directly impacts inhaler manufacturing.
4. Are there alternative sources for ProAir HFA’s ingredients?
Yes, multiple suppliers and manufacturers across different regions provide ingredients and device components, reducing dependency on single sources and increasing supply resilience.
5. How do supply chain disruptions impact the availability of ProAir HFA?
Disruptions in API, device component, or propellant production can lead to shortages, impacting patient access, particularly during global crises or regulatory shifts.
Conclusion
ProAir HFA's manufacturing ecosystem reflects a sophisticated interplay of global pharmaceutical suppliers, device manufacturers, and chemical producers. Ensuring a stable, compliant supply chain remains paramount for maintaining availability and meeting the needs of patients suffering from respiratory conditions. Strategic sourcing, diversified supplier relationships, and adherence to regulatory standards are the cornerstones of resilience for this essential inhaler product.
Sources:
[1] Pharmaceutical Technology, "Inhaler market dynamics," 2022.
[2] FDA and EMA regulatory guidelines on inhalers and API sourcing.
[3] Company websites and industry reports for Teva, Hikma, AstraZeneca, Chemours, and other suppliers.
More… ↓
